Apellis Pharmaceuticals to Host Conference Call on February 24, 2026, to Discuss Fourth Quarter and Full Year 2025 Financial Results

Rhea-AI Summary

Apellis Pharmaceuticals (Nasdaq: APLS) will host a conference call and webcast on Tuesday, February 24, 2026 at 8:30 a.m. ET to discuss fourth quarter and full year 2025 financial results.

Investors can preregister to access the live call by phone, view a live audio webcast and slides via the company’s Investors and Media Events and Presentations page, and access a replay for 30 days.

News Market Reaction – APLS

-1.10%

1 alert

-1.10% News Effect

On the day this news was published, APLS declined 1.10%, reflecting a mild negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Conference call date: February 24, 2026 Call time: 8:30 a.m. ET Webcast replay period: 30 days +4 more

7 metrics

Conference call date February 24, 2026 Fourth quarter and full year 2025 results call

Call time 8:30 a.m. ET Start time for earnings conference call

Webcast replay period 30 days Replay availability after the event

Approved C3 medicines 2 medicines C3-targeting therapies currently approved

Approved diseases 4 diseases Serious diseases treated by company’s C3 medicines

New complement class gap 15 years First new class of complement medicine in 15 years

Minimum patient age 12 years Age threshold for C3G or IC-MPGN treatment

Market Reality Check

Price: $40.39 Vol: Volume 2,598,456 is below...

low vol

$40.39 Last Close

Volume Volume 2,598,456 is below 20-day average of 3,952,661 (relative volume 0.66x). low

Technical Shares at 22.83 are trading slightly above 200-day MA of 22.13.

Peers on Argus

APLS fell 2.81% while peers showed mixed moves: SRRK +1.38%, TLX +0.85%, IMVT -0...

APLS fell 2.81% while peers showed mixed moves: SRRK +1.38%, TLX +0.85%, IMVT -0.72%, KYMR -0.28%, PTGX -0.18%, pointing to stock-specific trading.

Previous Conferences,earnings Reports

5 past events · Latest: Oct 16 (Neutral)

Same Type Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Oct 16	Earnings call notice	Neutral	-4.2%	Scheduled Q3 2025 results conference call and webcast details.
Jul 24	Earnings call notice	Neutral	+0.9%	Announced Q2 2025 results call timing and access information.
Apr 30	Earnings call notice	Neutral	+5.5%	Set date and logistics for Q1 2025 financial results call.
Feb 14	Earnings call notice	Neutral	-0.2%	Outlined plan for Q4 and full-year 2024 results conference call.
Oct 22	Earnings call notice	Neutral	+2.7%	Announced Q3 2024 results call with webcast and replay details.

Pattern Detected

Earnings-call scheduling headlines have historically led to modest, mixed price reactions around the announcement dates.

Recent Company History

Over the past year, Apellis has repeatedly issued "conference call to discuss results" announcements ahead of quarterly and annual reports. These conferences,earnings notices on Nov 5, 2024, Feb 28, 2025, May 7, 2025, Jul 31, 2025, and Oct 30, 2025 produced small positive and negative moves, averaging about 0.93%. Today’s scheduling of the Q4 and full-year 2025 call fits this established communication pattern without adding new financial figures.

Historical Comparison

+0.9% avg move · In the past year, Apellis issued 5 similar conferences/earnings call notices. Average move was about...

conferences,earnings

+0.9%

Average Historical Move conferences,earnings

In the past year, Apellis issued 5 similar conferences/earnings call notices. Average move was about 0.93%, indicating these scheduling updates typically prompted only modest stock reactions.

Recurring quarterly and annual earnings-call scheduling from late 2024 through 2025, maintaining a consistent investor communications pattern.

Market Pulse Summary

This announcement schedules Apellis’s fourth quarter and full year 2025 results call for February 24...

Analysis

This announcement schedules Apellis’s fourth quarter and full year 2025 results call for February 24, 2026 at 8:30 a.m. ET, with a webcast replay available for 30 days. It continues a recurring pattern of advance conferences/earnings notices that historically led to modest stock moves. Investors may focus on upcoming reported figures for its two C3-targeting medicines approved in 4 diseases and any updated strategic commentary.

Key Terms

biopharmaceutical, complement science, complement medicine, c3-targeting medicines, +3 more

7 terms

biopharmaceutical medical

"Apellis Pharmaceuticals, Inc. is a global biopharmaceutical company leading the way"

A biopharmaceutical is a medicine made from living organisms or their components—such as proteins, cells or genetic material—rather than chemically synthesized compounds. For investors, these products can command high prices and long patent protection but also carry bigger development, manufacturing and regulatory risks; think of them like handcrafted, high-tech products that can generate strong returns if they work, but are costly and complex to produce.

complement science medical

"leading the way in complement science to develop life-changing therapies"

Complement science is the study of the complement system, a set of proteins in the immune system that acts like a security alarm and cleanup crew: it helps detect invaders, flags them for removal, and amplifies immune responses. For investors, this matters because drugs or diagnostics that modulate this pathway can treat inflammatory and rare diseases, making them potential high-value targets in biotech pipelines and affecting clinical, regulatory, and market prospects.

complement medicine medical

"We ushered in the first new class of complement medicine in 15 years"

Complement medicine refers to therapies and products used alongside conventional medical treatment—such as herbal supplements, acupuncture, or mindfulness programs—rather than replacing standard care. Investors care because these offerings create additional consumer demand, revenue streams, and regulatory risk: their market success depends on public trust, scientific evidence, and health rules, so they can boost growth if accepted or pose reputational and legal downsides if not.

c3-targeting medicines medical

"now have two C3-targeting medicines approved to treat four serious diseases"

C3-targeting medicines are drugs designed to block or modify the activity of complement component 3 (C3), a central protein in the immune system’s inflammatory response. Think of C3 as a main switch in a building’s alarm system: changing its activity can stop overactive inflammation that damages tissues in certain rare and common diseases. Investors watch these drugs because they can fill large unmet medical needs and meaningfully change a company’s revenue prospects, but success depends heavily on clinical trial results, safety profiles, dosing convenience, and regulatory approval.

geographic atrophy medical

"the first-ever therapy for geographic atrophy, a leading cause of blindness"

Geographic atrophy is a progressive eye condition in which patches of light-sensing cells in the retina die, causing growing blind spots and ultimately significant central vision loss. For investors, it matters because the condition defines the market size and urgency for drugs, devices, and diagnostics — like a spreading hole in a photograph that companies aim to stop or repair — so clinical results, approvals, and reimbursement determine potential revenue and risk.

c3g medical

"treatment for patients 12 and older with C3G or primary IC-MPGN"

C3G is short for cyanidin-3-glucoside, a natural pigment found in many berries, cherries and other colorful plants that acts as an antioxidant. Investors watch C3G because it is used in dietary supplements, functional foods and cosmetic products, and claims about health benefits or new clinical evidence can change a product’s market size, regulatory scrutiny and sales — like a new ingredient that can boost demand if backed by credible research.

ic-mpgn medical

"patients 12 and older with C3G or primary IC-MPGN, two severe, rare kidney diseases"

A form of kidney inflammation where immune system debris builds up in the tiny blood-filtering units (glomeruli), causing thickening and scarring that reduces the kidney’s filtering ability. Think of it as small plumbing filters clogged by sticky particles; it matters to investors because it defines a clear medical need, shapes the design and length of clinical trials, and influences potential market size and regulatory scrutiny for drugs or diagnostics targeting this condition.

AI-generated analysis. Not financial advice.

WALTHAM, Mass., Feb. 10, 2026 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the company will host a conference call and webcast to discuss its fourth quarter and full year 2025 financial results on Tuesday, February 24, 2026 at 8:30 a.m. ET.

To access the live call by phone, please pre-register for the call here. A live audio webcast of the event and accompanying slides may also be accessed through the “Events and Presentations” page of the “Investors and Media” section of the company’s website. A replay of the webcast will be available for 30 days following the event.

About Apellis 
Apellis Pharmaceuticals, Inc. is a global biopharmaceutical company leading the way in complement science to develop life-changing therapies for some of the most challenging diseases patients face. We ushered in the first new class of complement medicine in 15 years and now have two C3-targeting medicines approved to treat four serious diseases. Breakthroughs for patients include the first-ever therapy for geographic atrophy, a leading cause of blindness, and the first treatment for patients 12 and older with C3G or primary IC-MPGN, two severe, rare kidney diseases. We believe we have only begun to unlock the potential of targeting C3 across many serious diseases. For more information, please visit http://apellis.com or follow us on LinkedIn and X.

Investor Contact:
Eva Stroynowski
ir@apellis.com
617.938.6229

FAQ

When will Apellis (APLS) present its Q4 and full year 2025 results?

Apellis will present results on February 24, 2026 at 8:30 a.m. ET. According to the company, the event will cover fourth quarter and full year 2025 financial results and include a live webcast and accompanying slides.

How can investors join the Apellis (APLS) earnings call on February 24, 2026?

Investors can join by phone after preregistering for the live call. According to the company, a live audio webcast and slides will also be available on the Investors and Media Events and Presentations page.

Will Apellis (APLS) provide a replay of the February 24, 2026 webcast?

Yes, a replay will be available for 30 days following the event. According to the company, the webcast replay and slides can be accessed via the company’s Events and Presentations page during that period.

Where can I find the slides for the Apellis (APLS) February 24, 2026 presentation?

Presentation slides will be posted on the company’s Investors and Media Events and Presentations page. According to the company, the slides accompany the live audio webcast for the fourth quarter and full year 2025 results.

Who should investors contact for questions about the Apellis (APLS) earnings call?

Investor inquiries can be directed to the listed investor contact, Eva Stroynowski. According to the company, contact details include email ir@apellis.com and phone 617.938.6229 for investor relations questions.